Prometheus Laboratories has received New York State approval for its proprietary Prometheus Crohn's Prognostic test, an advance in the company's Inflammatory Bowel Disease (IBD) franchise of diagnostic and prognostic tests.
The Prometheus Crohn’s Prognostic test combines six serologic markers and three genetic mutation markers to provide physicians with a personalized serogenetic profile for their patients.
The test enables physicians to quantify patients’ risk of developing disease complications over time and is designed to provide information to assist physicians in determining optimal treatment strategies for their Crohn’s patients.
Prometheus president and CEO Joseph Limber said the proprietary Prometheus Crohn’s Prognostic helps physicians in developing a more individualized treatment plan for each patient and better explain the risks and benefits of these treatments to their patients and their families.
"Prometheus is committed to continue its mission of contributing to personalized medicine by offering the GI community innovative tools to assist in the diagnosis, prognosis, and treatment of IBD patients," Limber said.